Adolescents with alopecia areata achieve hair regrowth with 80% or more of scalp coverage while taking the Janus kinase inhibitor baricitinib, a phase 3 study finds.

ORLANDO, FLA. — Janus kinase (JAK) inhibitors have revolutionized the treatment of alopecia areata (AA), and more drugs in this class are still in development for AA. However, a new therapy with ...

The findings from scientists at the Crnic Institute support the notion that JAK inhibitors are a valuable ... observed for ...

Maryanne Senna, MD, assistant professor of dermatology at Harvard Medical School, discusses the results of the case and the impact JAK inhibitors have had on the treatment of alopecia areata ...

Zhang J, et al. Efficacy and safety of ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of adult with severe alopecia areata (AA): a randomized, double-blind ...

Currently approved therapies for alopecia areata are all JAK inhibitors and carry boxed warning labels, King noted.

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

1 "With these data, baricitinib is the most well-studied JAK inhibitor in severe alopecia areata, a chronic immune system disorder that can have an especially devastating social and emotional ...

Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg Patients treated with baricitinib 4 mg saw significant ...

Approximately 40% of patients with AA experience first onset by 20 years of age. 2 "Early onset alopecia areata can be more severe, leading to extensive hair loss that frequently does not improve ...